This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aviezer, D. Articles by Yayon, A. Search for Related Content PubMed PubMed Citation Articles by Aviezer, D. Articles by Yayon, A.

Porphyrin Analogues as Novel Antagonists of Fibroblast Growth Factor and Vascular Endothelial Growth Factor Receptor Binding That Inhibit Endothelial Cell Proliferation, Tumor Progression, and Metastasis

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100 [D. A., S. C., M. D., A. S., A. Y.], and Department of Chemistry, Technion-Israel Institute of Technology, Haifa 32000 [N. K., N. G., Z. G.], Israel

Fibroblast growth factors (FGFs) and vascular endothelial growth factor (VEGF) play a pivotal role in the multistep pathway of tumor progression, metastasis, and angiogenesis. We have identified a porphyrin analogue, 5,10,15,20-tetrakis(methyl-4-pyridyl)-21H,23H-porphine-tetra-p-tosylate salt (TMPP), as a potent inhibitor of FGF2 and VEGF receptor binding and activation. TMPP demonstrated potent inhibition of binding of soluble FGF receptor 1 (FGFR1) to FGF2 immobilized on heparin at submicromolar concentrations. TMPP inhibits binding of radiolabeled FGF2 to FGFR in a cell-free system as well as to cells genetically engineered to express FGFR1. Furthermore, TMPP also inhibits the binding of VEGF to its tyrosine kinase receptor in a dose-dependent manner. In an in vitro angiogenic assay measuring the extent of endothelial cell growth, tube formation, and sprouting, TMPP dramatically reduced the extent of the FGF2-induced endothelial cell outgrowth and differentiation. In a Lewis lung carcinoma model, mice receiving TMPP showed a marked inhibition of both primary tumor progression and lung metastases development, with nearly total inhibition of the metastatic phenotype upon alternate daily injections of TMPP at 25 µg/g of body mass. Finally, novel meso-pyridylium-substituted, nonsymmetric porphyrins, as well as a novel corrole-based derivative, with >50-fold increase in activity in vitro, had a significantly improved efficacy in blocking tumor progression and metastasis in vivo.

This article has been cited by other articles:

				H. Agadjanian, J. Ma, A. Rentsendorj, V. Valluripalli, J. Y. Hwang, A. Mahammed, D. L. Farkas, H. B. Gray, Z. Gross, and L. K. Medina-Kauwe Tumor detection and elimination by a targeted gallium corrole PNAS, April 14, 2009; 106(15): 6105 - 6110. [Abstract] [Full Text] [PDF]

				S. Fletcher and A. D Hamilton Targeting protein-protein interactions by rational design: mimicry of protein surfaces J R Soc Interface, April 22, 2006; 3(7): 215 - 233. [Abstract] [Full Text] [PDF]

				Y. Ueda, T. Yamagishi, K. Samata, H. Ikeya, N. Hirayama, H. Takashima, S. Nakaike, M. Tanaka, and I. Saiki A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155 Mol. Cancer Ther., November 1, 2003; 2(11): 1105 - 1111. [Abstract] [Full Text] [PDF]

				S. J. Kwon, A. L. de Boer, R. Petri, and C. Schmidt-Dannert High-Level Production of Porphyrins in Metabolically Engineered Escherichia coli: Systematic Extension of a Pathway Assembled from Overexpressed Genes Involved in Heme Biosynthesis Appl. Envir. Microbiol., August 1, 2003; 69(8): 4875 - 4883. [Abstract] [Full Text] [PDF]

				A. Facchiano, K. Russo, A. M. Facchiano, F. De Marchis, F. Facchiano, D. Ribatti, M. S. Aguzzi, and M. C. Capogrossi Identification of a Novel Domain of Fibroblast Growth Factor 2 Controlling Its Angiogenic Properties J. Biol. Chem., February 28, 2003; 278(10): 8751 - 8760. [Abstract] [Full Text] [PDF]

				A. Segev, D. Aviezer, M. Safran, Z. Gross, and A. Yayon Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist Cardiovasc Res, January 1, 2002; 53(1): 232 - 241. [Abstract] [Full Text] [PDF]

				D. Aviezer, A. P. Seddon, M. J. Wildey, P. Bohlen, and A. Yayon Development of a High Throughput Screening Assay for Inhibitors of Fibroblast Growth Factor-Receptor-Heparin Interactions J Biomol Screen, June 1, 2001; 6(3): 171 - 177. [Abstract] [PDF]